Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for chronic post-stroke disability
ACTRN12620001011976Phase 2Terminated
- Sponsor
- Florey Institute of Neuroscience and Mental Health
- Start
- Nov 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in stroke, ischemic stroke and brain hemorrhage (ICH) comparing Etanercept with Placebo (2 arms). Primary endpoint: Change in overall quality of life score at day 28. Started Nov 2020; status: terminated.
02
Drugs
etanercept
03
Conditions
strokeischemic strokebrain hemorrhage (ICH)
Beyond the preview
Go deeper on ACTRN12620001011976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001011976.